Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Company profile
Ticker
CTLT
Exchange
Website
CEO
Mr. Alessandro Maselli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PTS Holdings Corp.
SEC CIK
Corporate docs
Subsidiaries
Catalent Anagni S.r.l. • Catalent Belgium S.A. • Catalent Belgium Holding S.A. • Catalent Brasil Ltda • Catalent China Holdings Limited • Catalent Cosmetics AG • Catalent CTS, LLC • Catalent CTS (Edinburgh) Limited • Catalent CTS (Kansas City), LLC • Catalent CTS (Singapore) Pvt Ltd ...
CTLT stock data
Latest filings (excl ownership)
10-K
2024 FY
Annual report
6 Sep 24
NT 10-K
Notice of late annual filing
30 Aug 24
8-K
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
29 Aug 24
8-K
Catalent Stockholders Approve Transaction with Novo Holdings
29 May 24
DEFA14A
Additional proxy soliciting materials
16 May 24
8-K
Other Events
16 May 24
10-Q
2024 Q3
Quarterly report
8 May 24
8-K
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
8 May 24
DEFA14A
Additional proxy soliciting materials
3 May 24
8-K
Other Events
3 May 24
Transcripts
CTLT
Earnings call transcript
2024 Q1
15 Nov 23
CTLT
Earnings call transcript
2023 Q4
29 Aug 23
CTLT
Earnings call transcript
2023 Q4
29 Aug 23
CTLT
Earnings call transcript
2023 Q3
12 Jun 23
CTLT
Earnings call transcript
2023 Q3
12 Jun 23
CTLT
Earnings call transcript
2023 Q3
19 May 23
CTLT
Earnings call transcript
2023 Q2
7 Feb 23
CTLT
Earnings call transcript
2023 Q1
1 Nov 22
CTLT
Earnings call transcript
2022 Q4
29 Aug 22
CTLT
Earnings call transcript
2022 Q3
3 May 22
Latest ownership filings
4
Ricky Hopson
5 Aug 24
4
Scott Gunther
5 Aug 24
4
Joseph Anthony Ferraro
5 Aug 24
4
Lisa Evoli
5 Aug 24
4
Aristippos Gennadios
5 Aug 24
144
Notice of proposed sale of securities
5 Aug 24
144
Notice of proposed sale of securities
2 Aug 24
144
Notice of proposed sale of securities
2 Aug 24
144
Notice of proposed sale of securities
2 Aug 24
144
Notice of proposed sale of securities
2 Aug 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 24 | Jun 23 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 289.00 mm | 289.00 mm | 289.00 mm | 289.00 mm | 289.00 mm | 289.00 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 79.92 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | 219.26 mm | n/a | n/a |
Cash remaining | n/a | n/a | n/a | 69.74 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | n/a | 0.9 | n/a | n/a |
Institutional ownership, Q2 2024
95.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 440 |
Opened positions | 76 |
Closed positions | 56 |
Increased positions | 139 |
Reduced positions | 162 |
13F shares | Current |
---|---|
Total value | 8.63 tn |
Total shares | 173.79 mm |
Total puts | 836.42 k |
Total calls | 360.54 k |
Total put/call ratio | 2.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 20.39 mm | $1.15 tn |
BLK BlackRock | 15.35 mm | $863.37 bn |
NMR Nomura | 11.00 mm | $618.43 bn |
Green Equity Investors VII | 7.83 mm | $781.37 mm |
STT State Street | 7.34 mm | $412.62 bn |
BCS Barclays | 4.97 mm | $279.24 mm |
Capital World Investors | 4.91 mm | $276.19 bn |
T. Rowe Price | 4.91 mm | $276.09 mm |
Norges Bank | 4.59 mm | $258.03 bn |
Veritas Asset Management | 4.40 mm | $247.15 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Aug 24 | Gennadios Aristippos | Common Stock | Sell | Dispose S | No | No | 59.55 | 1,169 | 69.61 k | 113,724 |
2 Aug 24 | Evoli Lisa | Common Stock | Sell | Dispose S | No | No | 59.67 | 3,859 | 230.27 k | 39,366 |
2 Aug 24 | Ferraro Joseph Anthony | Common Stock | Sell | Dispose S | No | No | 59.58 | 608 | 36.22 k | 24,287 |
2 Aug 24 | Gunther Scott | Common Stock | Sell | Dispose S | No | No | 59.55 | 666 | 39.66 k | 39,635 |
2 Aug 24 | Ricky Hopson | Common Stock | Sell | Dispose S | No | No | 59.56 | 662 | 39.43 k | 29,974 |
News
William Blair Reiterates Market Perform on Catalent
3 Sep 24
Catalent Expands Its Facility Capabilities in Germany
17 Jul 24
Catalent Completes $25M Upgrade To Schorndorf Site, Featuring Expanded Storage And New FastChain Area
16 Jul 24
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
11 Jul 24